Pages that link to "Q22306481"

The following pages link to Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications (Q22306481):

Displaying 31 items.

• Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease (Q24187073) (← links)
• Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease (Q24198068) (← links)
• Cardiac safety of tiotropium in patients with COPD: a combined analysis of Holter-ECG data from four randomised clinical trials (Q30877371) (← links)
• Cardiovascular safety of tiotropium Respimat vs HandiHaler in the routine clinical practice: A population-based cohort study (Q33590384) (← links)
• Chronic obstructive pulmonary disease: respiratory review of 2014. (Q34440060) (← links)
• Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary (Q34550471) (← links)
• Risk factors influencing the prescription of tiotropium Respimat formulation: a population-based cohort study. (Q35675649) (← links)
• Risk of Stroke and Post-Stroke Adverse Events in Patients with Exacerbations of Chronic Obstructive Pulmonary Disease (Q36242932) (← links)
• Effect of inhaled drugs on anxiety and depression in patients with chronic obstructive pulmonary disease: a prospective observational study (Q36802786) (← links)
• Efficacy and safety of eco-friendly inhalers: focus on combination ipratropium bromide and albuterol in chronic obstructive pulmonary disease (Q36813641) (← links)
• One-year mortality associated with COPD treatment: a comparison of tiotropium and long-acting beta2-agonists in three Italian regions: results from the OUTPUL study (Q37343961) (← links)
• Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD. (Q37468663) (← links)
• Drug safety assessment in clinical trials: methodological challenges and opportunities (Q38035953) (← links)
• Chronic obstructive pulmonary disease and cardiovascular disease (Q38111151) (← links)
• Pharmacological consequences of inhaled drug delivery to small airways in the treatment of asthma. (Q38239365) (← links)
• Does Cardiovascular Comorbidity Influence the Prescribing of Bronchodilators in Chronic Obstructive Pulmonary Disease? (Q38749254) (← links)
• Total anticholinergic burden and risk of mortality and cardiovascular disease over 10 years in 21,636 middle-aged and older men and women of EPIC-Norfolk prospective population study (Q39093399) (← links)
• This patient is not breathing properly: is this COPD, heart failure, or neither? (Q39232408) (← links)
• Comparative Cardiovascular and Cerebrovascular Safety of Inhaled Long-Acting Bronchodilators in Patients with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study. (Q40957631) (← links)
• Thorax editorial by Jenkins and Beasley related to tiotropium respimat (Q43800626) (← links)
• Impact of long-acting bronchodilators and exposure to inhaled corticosteroids on mortality in COPD: a real-life retrospective cohort study. (Q45952249) (← links)
• Differences in clinical characteristics, management and short-term outcome between acute heart failure patients chronic obstructive pulmonary disease and those without this co-morbidity (Q46738415) (← links)
• Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease. (Q47792766) (← links)
• Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary (Q47984024) (← links)
• Baseline anticholinergic burden from medications predicts incident fatal and non-fatal stroke in the EPIC-Norfolk general population (Q49922706) (← links)
• Stroke risk among patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. (Q53069143) (← links)
• An anticholinergic burden score for German prescribers: score development (Q57279785) (← links)
• Anticholinergics aggravate the imbalance of the autonomic nervous system in stable chronic obstructive pulmonary disease (Q64059725) (← links)
• Major comorbidities lead to the risk of adverse cardiovascular events in chronic obstructive pulmonary disease patients using inhaled long-acting bronchodilators: a case-control study (Q91650688) (← links)
• Efficacy and Safety of Nebulized Glycopyrrolate/eFlow® Closed System in Patients with Moderate-to-Very-Severe Chronic Obstructive Pulmonary Disease with Pre-Existing Cardiovascular Risk Factors (Q91671242) (← links)
• Management of cardiovascular comorbidities in chronic obstructive pulmonary disease patients (Q97538245) (← links)